Raydiant Oximetry is a Rosenman Innovator company.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Raydiant Oximetry, which is developing an innovative fetal monitor to improve outcomes for mothers and babies during childbirth, has closed a $5.6 million Series A funding round led by VCapital. It follows on the heels of a recent string of funding rounds, grants and an exit by fellow Fogarty companies Enspectra, CyberHeart, Materna and G-Tech.

“VCapital screens around 1,500 deals per year and only invests in four to five select companies. Raydiant Oximetry stood out based on its attention to detail, communication and interest in taking on a true partner, beyond just the financial elements,”said Ryan Kole, partner, VCapital. “We have great confidence in the team and are extremely delighted to be part of their journey as they improve maternal and infant health.”

Raydiant’s investors included AngelMD, MD Angels, Band of Angels, the Mass Medical Angels, Rhia Ventures and Avestria Ventures.

Read the full story at the Fogarty Institute for Innovation